XML 76 R56.htm IDEA: XBRL DOCUMENT v3.25.1
Net Loss per Share - Schedule of computation of basic and diluted net loss per share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 6 Months Ended 12 Months Ended
Dec. 31, 2022
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Numerator        
Net loss before noncontrolling interest $ (54,503) $ (163,335) $ (135,447) $ (148,135)
Less: Net loss attributable to noncontrolling interests $ (40,103) $ (102,149) $ (99,979)  
Antidilutive securities        
Earnout Rights   17,500,000 17,500,000 17,500,000
Stock options granted under the 2022 Equity Incentive Plan 9,504,715 21,449,920 14,680,109 9,504,715
Legacy Scs[Member]        
Antidilutive securities        
Unvested Restricted Stock Rights   0 0 50,000
Legacy SCS Restricted Share Units   0 0 50,000
Restricted Stock [Member]        
Antidilutive securities        
Unvested Restricted Stock Rights   1,755,686 3,565,753 8,369,796
Legacy SCS Restricted Share Units   1,755,686 3,565,753 8,369,796
Common Class A [Member]        
Numerator        
Net loss available to Class A ordinary shareholders of ProKidney Corp., Basic $ (14,400) $ (61,186) $ (35,468)  
Net loss available to Class A ordinary shareholders of ProKidney Corp,. Diluted $ (14,400) $ (61,186) $ (35,468)  
Denominator        
Weighted average Class A ordinary shares outstanding, Basic 61,540,231 97,916,193 61,714,225 61,540,231
Weighted average Class A ordinary shares outstanding, Diluted 61,540,231 97,916,193 61,714,225 61,540,231
Net loss per share attributable to Class A ordinary shares, Basic $ (0.23) $ (0.62) $ (0.57) $ (0.23)
Net loss per share attributable to Class A ordinary shares, Diluted $ (0.23) $ (0.62) $ (0.57) $ (0.23)
Antidilutive securities        
Ordinary shares, shares outstanding   128,054,417 59,880,347  
Common Class B [Member]        
Antidilutive securities        
Ordinary shares, shares outstanding 171,578,320 163,693,707 168,297,916 171,578,320